-
Published on Nov 16, 2016
Northland
Capital analyst Vadim Alexander tells Proactive that by having another
promising programme, ImmuPharma PLC (LON:IMM) is setting itself up for
future growth.
The firm’s IPP-204106 cancer treatment is being featured in Cancer Research, the medical journal of the American Association of Cancer Research.
“The journal is quite well-respected and this is the second time that they’re in this Cancer Research paper,” Alxeandre explains.
“This is just a follow on to their [prior] good research.”
This is ImmuPharma’s second most advanced programme, with its Lupuzor treatment for lupus due to undergo Phase III in the near future.
“You want to see diversification of the pipeline and they have now two clinical programmes,” adds Alexandre.
No comments:
Post a Comment